Enhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo-D-arginine

被引:11
作者
Chung, Jee Young [1 ,2 ]
Ul Ain, Qurrat [1 ,2 ]
Lee, Hyun Lin [1 ]
Kim, So-Mi [1 ]
Kim, Yong-Hee [1 ,2 ]
机构
[1] Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Dept Bioengn, 17 Haengdang Dong, Seoul 133791, South Korea
[2] Hanyang Univ, BK Plus Future Biopharmaceut Human Resources Trai, 17 Haengdang Dong, Seoul 133791, South Korea
基金
新加坡国家研究基金会;
关键词
angiogenesis; enhanced permeability and enhanced effect; siVEGF delivery; PEGylation; antitumor therapy; SMALL-INTERFERING RNA; SIRNA DELIVERY; GENE DELIVERY; IN-VIVO; CANCER-THERAPY; PEPTIDE; NANOPARTICLES; CIRCULATION; POLYPLEXES; CARRIER;
D O I
10.1021/acs.molpharmaceut.7b00282
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Angiogenesis mainly mediated by upregulation of vascular endothelial growth factor (VEGF) provides a hallmark of rapidly proliferating tumor cells and an essential component of the tumor growth and microenvironment, making it a targetable process for antitumor therapy. RNA interference (RNAi) provides a very effective tool for developing antitumor therapies; however, its application to date has been hampered due to the lack of efficient small interfering RNA (siRNA) delivery systems in vivo. Here, we report a polymeric gene carrier system based on PEGylation of a cationic cysteine-ended 9-mer arginine oligopeptide (CR9C), which provides effective siRNA systemic delivery and specifically suppresses VEGF (siVEGF). The PEG500-CR9C/siVEGF oligopeptoplex provided improved blood circulation, enhanced protection from serum proteases, reduced uptake in the liver and kidneys, enhanced tumor targeting, and down-regulated intratumoral VEGF level, which comprehensively resulted in improved antitumor efficacy without significant toxicity in vivo. PEG500-CR9C has a great potential for safe and efficient siRNA delivery with diverse applications.
引用
收藏
页码:3059 / 3068
页数:10
相关论文
共 38 条
[1]   Principles of nanoparticle design for overcoming biological barriers to drug delivery [J].
Blanco, Elvin ;
Shen, Haifa ;
Ferrari, Mauro .
NATURE BIOTECHNOLOGY, 2015, 33 (09) :941-951
[2]   Magnetic nanoparticles and targeted drug delivering [J].
Chomoucka, Jana ;
Drbohlavova, Jana ;
Huska, Dalibor ;
Adam, Vojtech ;
Kizek, Rene ;
Hubalek, Jaromir .
PHARMACOLOGICAL RESEARCH, 2010, 62 (02) :144-149
[3]  
Dahlman JE, 2014, NAT NANOTECHNOL, V9, P648, DOI [10.1038/nnano.2014.84, 10.1038/NNANO.2014.84]
[4]   Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles [J].
Davis, Mark E. ;
Zuckerman, Jonathan E. ;
Choi, Chung Hang J. ;
Seligson, David ;
Tolcher, Anthony ;
Alabi, Christopher A. ;
Yen, Yun ;
Heidel, Jeremy D. ;
Ribas, Antoni .
NATURE, 2010, 464 (7291) :1067-U140
[5]   Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [J].
Ferrara, N ;
Hillan, KJ ;
Novotny, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :328-335
[6]   Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery [J].
Gary, Dana J. ;
Puri, Nitin ;
Won, You-Yeon .
JOURNAL OF CONTROLLED RELEASE, 2007, 121 (1-2) :64-73
[7]   Influence of Nano-Carrier Architecture on in Vitro siRNA Delivery Performance and in Vivo Biodistribution: Polyplexes vs Micelleplexes [J].
Gary, Dana J. ;
Lee, Hoyoung ;
Sharma, Rahul ;
Lee, Jae-Sung ;
Kim, Youngwook ;
Cui, Zheng Yun ;
Jia, Di ;
Bowman, Valorie D. ;
Chipman, Paul R. ;
Wan, Lei ;
Zou, Yi ;
Mao, Guangzhao ;
Park, Keunchil ;
Herbert, Brittney-Shea ;
Konieczny, Stephen F. ;
Won, You-Yeon .
ACS NANO, 2011, 5 (05) :3493-3505
[8]   Suppression of Hepatic Inflammation via Systemic siRNA Delivery by Membrane-Disruptive and Endosomolytic Helical Polypeptide Hybrid Nanoparticles [J].
He, Hua ;
Zheng, Nan ;
Song, Ziyuan ;
Kim, Kyung Hoon ;
Yao, Catherine ;
Zhang, Rujing ;
Zhang, Chenglin ;
Huang, Yuhui ;
Uckun, Fatih M. ;
Cheng, Jianjun ;
Zhang, Yanfeng ;
Yin, Lichen .
ACS NANO, 2016, 10 (02) :1859-1870
[9]   Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma [J].
Hu-Lieskovan, S ;
Heidel, JD ;
Bartlett, DW ;
Davis, ME ;
Triche, TJ .
CANCER RESEARCH, 2005, 65 (19) :8984-8992
[10]   Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antiangiogenesis and Apoptosis [J].
Huang, Shixian ;
Shao, Kun ;
Liu, Yang ;
Kuang, Yuyang ;
Li, Jianfeng ;
An, Sal ;
Guo, Yubo ;
Ma, Haojun ;
Jiang, Chen .
ACS NANO, 2013, 7 (03) :2860-2871